Mannkind corporation
MNKD 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
MNKD 近期報酬表現
0.23%
Mannkind corporation
2.92%
同產業平均
1.26%
S&P500
與 MNKD 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
FOLD | Amicus therapeutics, inc | 3 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
UTHR | United therapeutics corporation | 5 分 | 5 分 | 4 分 | 3 分 | 1 分 | |
DNLI | Denali therapeutics inc | 4 分 | 2 分 | 3 分 | 3 分 | 1 分 | |
MIRA | Mira pharmaceuticals inc | - | 2 分 | 2 分 | 1 分 | 1 分 | |
INSM | Insmed inc | 4 分 | 1 分 | 2 分 | 3 分 | 1 分 |
- FOLD Amicus therapeutics, inc價值 3 分趨勢 1 分波段 2 分籌碼 3 分股利 1 分查看更多
MNKD 公司資訊
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).